What Veeva Systems Does & How It Makes Money (VEEV)
Updated October 2026 · reflects Veeva Systems's latest reported financials
Cloud software provider for pharmaceutical and life sciences companies. Veeva mainly earns recurring revenue from cloud software and data products that life sciences customers pay for on an ongoing basis.
How Veeva Systems makes money
Veeva mainly earns recurring revenue from cloud software and data products that life sciences customers pay for on an ongoing basis. It also charges for professional services such as implementation, consulting, training, and managed administration.
What Veeva Systems does
Veeva Systems is a cloud software company focused specifically on the life sciences industry, serving pharmaceutical, biotech, and related customers across North America, Europe, Asia Pacific, and other regions. It organizes its offerings into several clouds: Commercial Cloud (Vault CRM, Medical, PromoMats content management, and Crossix brand analytics), Data Cloud (OpenData customer reference data, Link, Compass patient data, and CRM Pulse engagement metrics), Development Cloud (clinical trial execution and data management, Safety, and RIM regulatory tools), and Quality Cloud, which also serves consumer products companies. On top of its software and data, Veeva provides professional and support services, including implementation, solution design, data migration, systems integration, training, business consulting, and outsourced systems administration. Founded in 2007 as Verticals onDemand and renamed in 2009, the company is headquartered in Pleasanton, California.
Products & services
- Veeva Vault CRM Suite
- Veeva PromoMats
- Veeva Crossix
- Veeva OpenData
- Veeva Clinical Platform
- Veeva Quality Cloud
What is Veeva Systems worth?
On an owner-earnings DCF, Veeva Systems's most-likely value is about $370 versus a recent price near $296 (25% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$111) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
IQVIA (IQV) · Viatris (VTRS) · Revvity (RVTY) · AbbVie (ABBV) · CVS Health (CVS)
TacticScale